BioSpace News Archive

Siolta Therapeutics, a clinical-stage biotech company, announced it has raised $30M in a series B investment round to support the clinical development of its lead product, STMC-103H.

Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix ® ), an award-winning life sciences innovator and exporter, announces it is has been invited to present about the performance of its COVID-19 in-vitro diagnostics (IVD) quality assessment products at “ECCVID,” a virtual conference on Coronavirus disease organized by the European Society for Clinical Microbiology and Infectious Diseases (ESCMID), taking place September 23-25, 2020

Global, Multi-Program Collaboration Now Includes Anokion’s Novel Product Candidates for Celiac Disease, in addition to Multiple Sclerosis and the Platform CAMBRIDGE, Mass. & LAUSANNE, Switzerland--( BUSINESS WIRE )-- Anokion SA , a Swiss biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced the expansion of an exclusive global collaboration agreement with Bristol Myers Squibb, focused

Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company, announced that the U.S. Food and Drug Administration has granted Fast Track designation to GT005 for the treatment of geographic atrophy secondary to dry age-related macular degeneration.

Artificial implants are used to augment or replace any bodily part or function. These are made of materials which are inert to the body’s immune mechanism, so as to not elicit allergic reactions.

RNA-based therapeutics and vaccines refer to prophylactic medications, which are generally used in the treatment of diverse critical diseases including diabetes, cancer, tuberculosis, and several cardiovascular conditions.

ENTEROME SA announces that Pierre Belichard, Chief Executive Officer, and Christophe Bonny, Chief Scientific Officer, will present at the Jefferies Virtual Next Generation IBD Therapeutics Summit, which will take place September 23-24, 2020.

RadNet, Inc., a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, announced that Mark Stolper, Executive Vice President and Chief Financial Officer, will be presenting at the Sidoti & Company Fall 2020 Conference on Wednesday, September 23rd at 12:15 p.m. Eastern Time.

ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced today initiation of a program to construct and test a multivalent peptide vaccine for Alzheimer’s disease (AD). The critical first steps in vaccine development will be carried out by VIDO-Inte